Opendata, web and dolomites


Morphogenetically active blood vessels: Proof-of-Concept

Total Cost €


EC-Contrib. €






 MorphoVES-PoC project word cloud

Explore the words cloud of the MorphoVES-PoC project. It provides you a very rough idea of what is the project "MorphoVES-PoC" about.

home    processed    printable    combine    extruder    msdvgs    durability    requiring    definitively    economical    synthetic    incl    disclose    backbone    patients    mortality    view    quality    artificial    pet    vessel    poc    diseases    strength    life    gathered    charged    blood    biopolymers    268476    besides    physiological    clinics    group    disorders    formulations    toxic    bioactive    active    functionally    likewise    frame    inorganic    optimal    urgently    erc    surgery    made    gene    allowed    differentiation    biomineral    data    cardiovascular    worldwide    vessels    performed    terephthalate    cationic    lt    discovered    unexpectedly    small    sponge    polymers    implants    linkers    biocompatibility    biodegradable    device    prostheses    anionic    advantages    natural    mm    causes    biosilica    morphogenetically    polyethylene    bio    physical    vascular    polyphosphate    clear    potencies    expanded    convinced    unprecedented    biosynthesis    diameter    modular    preferentially    insufficient    biomedical    grant    materials    handle    attractive    superior    eptfe    experimental    fabrication    bypass    biofunctional    grafts    polytetrafluoroethylene   

Project "MorphoVES-PoC" data sheet

The following table provides information about the project.


Organization address
address: Langenbeckstrasse 1
city: Mainz
postcode: 55131

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 149˙962 €
 EC max contribution 149˙962 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2016-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

'Cardiovascular diseases are the leading causes of mortality in Europe and worldwide. Currently, synthetic prostheses used in bypass vascular surgery are produced from polyethylene terephthalate [PET] and expanded polytetrafluoroethylene [ePTFE]. Those materials show less than optimal, insufficient biocompatibility and durability properties, especially if used for SMALL DIAMETER BLOOD VESSELS. Within the frame of ERC Advanced Grant “BIOSILICA” (From gene to biomineral: Biosynthesis and application of sponge biosilica; Grant No. 268476), we unexpectedly discovered that distinct natural, biodegradable and biofunctional polymers, including biosilica and inorganic polyphosphate (anionic), are not only bio-printable but also morphogenetically active. Likewise attractive is that those biopolymers can be functionally processed by non-toxic and charged (cationic) linkers with growth/differentiation potencies. Therefore, these formulations, backbone polymers and bioactive linkers, allowed the fabrication of unprecedented “Modular Small Diameter Vascular Grafts (MSDVGs)' which combine in an optimal way physical strength with physiological activity. Furthermore, the fabrication of the synthetic vessels is performed by a home-made, easy to handle, extruder device which has been developed by our group. Therefore, this new ERC-PoC project will provide small diameter (< 6 mm) blood vessel implants (incl. the fabrication device - the extruder) urgently required in clinics, with superior properties and at low-costs, at the end of the project. We are definitively convinced that, in view of their advantages, our vessels will be preferentially used for patients requiring bypass surgery. The experimental data gathered disclose that we have in hand a product with a clear biomedical application potential. Besides of their economical value, our new type of artificial blood vessel will certainly improve the quality of life and well-being of patients with cardiovascular disorders.'


year authors and title journal last update
List of publications.
2016 Werner E. G. Müller, Maximilian Ackermann, Emad Tolba, Meik Neufurth, Shunfeng Wang, Heinz C. Schröder, Xiaohong Wang
A bio-imitating approach to fabricate an artificial matrix for cartilage tissue engineering using magnesium-polyphosphate and hyaluronic acid
published pages: 88559-88570, ISSN: 2046-2069, DOI: 10.1039/C6RA17043A
RSC Adv. 6/91 2019-07-24
2015 Meik Neufurth, Xiaohong Wang, Emad Tolba, Bernhard Dorweiler, Heinz C. Schröder, Thorben Link, Bärbel Diehl-Seifert, Werner E. G. Müller
Modular Small Diameter Vascular Grafts with Bioactive Functionalities
published pages: e0133632, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0133632
PLOS ONE 10/7 2019-07-24
2016 Xiaohong Wang, Heinz C. Schröder, Werner E. G. Müller
Polyphosphate as a metabolic fuel in Metazoa: A foundational breakthrough invention for biomedical applications
published pages: 11-30, ISSN: 1860-6768, DOI: 10.1002/biot.201500168
Biotechnology Journal 11/1 2019-07-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MORPHOVES-POC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MORPHOVES-POC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More  


The Mass Politics of Disintegration

Read More  

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More